Interestingly one of the upstream regulatory genes of this pathway affected by bortezomib, PIK3CG (Figure 1 ), is a member of the PI3K complex, a main regulator of the PI3K/Akt pathway involved in the pathogenesis of MCL. 4 Analyzing the impact of bortezomib on the PI3K/Akt pathway members, we could show that exposure to bortezomib results in dephosphorylation of Akt on Ser273 accompanied by dephosphorylation of glycogen synthase kinase 3a/b and downregulation of CyclinD1 (CCND1) protein (Figures 2a-d ) in those cell lines with Akt protein downregulation. These findings are confirming previous studies that CCND1 is regulated by Akt via glycogen synthase kinase 3. 4 CyclinD1 gene expression is activated by Wnt/b-catenin signaling, with glycogen synthase kinase 3 having a critical role. In fact CCND1 degradation is influenced by glycogen synthase kinase 3b. 4 Several studies have shown that glycogen synthase kinase 3b Ser9 is phosphorylated by Akt. 5 In conclusion our results suggest that downregulation of CCND1 after bortezomib exposure is mediated through regulation of Akt ( Figure 1 ).
Another downstream target of the PI3K/Akt pathway is mammalian target of rapamycin (mTOR). The mTOR signaling pathway is activated and may contribute to cell cycle progression and tumor cell survival in MCL. 4 mTOR is a serine-threonine kinase downstream of Akt, which catalytic subunit consists of the two multi-protein complexes mTORC1 (mTOR-Raptor) and mTORC2 (mTOR-Rictor), which have distinct substrates and mechanisms of activation. 4 Analogs of rapamycin, a mTOR inhibitor, which blocks some of the mTORC1 functions but does not have an effect on mTORC2, has already been shown highly active in clinical trials 4 and has been recently registered for the treatment of relapsed MCL in Europe. In our study we could show that beside moderate
GSK3α/β 4 but also apoptosis. Thus, bortezomib acts on both complexes simultaneously and the negative feedback loop activating Akt via mTORC2 due to inhibition of mTORC1, described for rapamycin and analogs, 4 will be inhibited (Figure 1 ). Bortezomib also induced dephosphorylation and downregulation of substrates of TORC1, 4E-BP1 and p70S6. It is known that phosphorylation of 4E-BP1 is a crucial step in the oncogenic pathway downstream of Akt/mTOR and results in increased translation of eIF-4E-dependent proteins, like cyclinD1, BCL2 and c-myc. 4 Therefore dephosphorylation of 4E-BP1 should lead to Letters to the Editor decrease of translation efficiency of the target proteins (Figure 1) . However, only downregulation of CCND1 was detected, while Bcl2 and c-myc were not significantly influenced except in one cell line, HBL-2, with c-myc downregulation (Figure 2d ). Thus, an alternative mechanism of translation initiation could use an internal ribosomal entry site (IRES). 6 In fact c-myc, 7 Bcl2 (ref. 8) and CCND1 (ref. 9) mRNAs contain an internal ribosomal entry site in the 5 0 untranslated regions that maintain protein expression after a number of pathophysiological signals including apoptosis, genotoxic stress and viral infection. 9 Importantly, the internal ribosomal entry site can stimulate translation initiation during the G2/M phase whereas cap-dependent protein synthesis is inhibited. 10 These data may explain that in our study Bcl2 and c-myc proteins were not downregulated despite the observed cell apoptosis. Nevertheless the downregulation of CCND1 by bortezomib correlated with that of eIF-4E expression, a translation initiation factor of cap-dependent translation initiation. Interestingly eIF-4E phosphorylation was downregulated in concordance with the downregulation of MAP kinase interacting kinase 1, which phosphorylates EIF-4E 11 ( Figure 2g ). The mitogenactivated protein kinase (MAPK) signaling is another downstream target of Akt and is linked to the mTOR signaling through MAP kinase interacting kinase. In the present study protein expression of other downstream targets of this signal pathway, namely the mitogen-activated protein kinase (MEK)1/2 and p44/42MAPK, as well as their phosphorylation status, were heterogeneously affected by bortezomib (Supplementary Figure 1) . Based on the diverse regulation of MEK1/2, p44/42 and MAP kinase interacting kinase our data let suggest that the mitogen-activated protein kinase pathway does not have a major role in the mechanism of action of bortezomib in MCL. A recent study suggests that PP2A negatively regulates eIF-4E phosphorylation and eIF4F complex assembly through dephosphorylation of MAP kinase interacting kinase and eIF-4E 12 independent of the p38MAPK pathway. Interestingly we could show that bortezomib downregulates Cip2a, an inhibitor of PP2A and overexpressed in several human malignancies, 13 mainly on the mRNA level (up to 70% reduction of mRNA levels in both cell lines) but also on the protein level in two MCL cell lines (Jeko-1 and Hbl-2) (Figure 2e ). These results would support findings from Lin et al.
14 that PP2A, regulated by Cip2a, may have a major role in the bortezomib induced downregulation of phAkt and the subsequent apoptosis. Accordingly in patient samples bortezomib also had an impact on members of the PI3K/mTOR pathway with a predominant effect on protein dephosphorylation. This enhanced dephosphorylation may explain the increased p53 protein in bortezomib-treated patient samples as the inhibitory effect of mdm2 on p53 might be abrogated through dephosphorylation. 15 Nevertheless, the decrease of upstream signaling activity seems to have an additional role in the bortezomib induced influence on the PI3K/ mTOR pathway as we could demonstrate downregulation of the overall protein expression of the phosphoinositide-dependent protein kinase 1 (PDK1) in the MCL cell line Hbl-2 (Figure 2f) .
In summary, our data confirm that members of the PI3K/mTOR pathway are targeted by bortezomib and that this pathway is involved in the mode of action of bortezomib (Figure 1) . These results may have important implications for the development of future combined approaches in mantle cell lymphoma, based on the identified molecular mechanisms of proteasome inhibitors and other small molecules targeting the PI3K/mTOR-or related (B-ceIl receptor) pathways.
